The estimated Net Worth of Amit Sachdev is at least $85.7 Million dollars as of 15 May 2024. Mr. Sachdev owns over 32 units of Vertex Pharmaceuticals stock worth over $26,264,991 and over the last 17 years he sold VRTX stock worth over $53,285,622. In addition, he makes $6,197,050 as Executive Vice President and Chief Regulatory Officer and Chief of Staff to the CEO at Vertex Pharmaceuticals.
Amit has made over 89 trades of the Vertex Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 32 units of VRTX stock worth $13,790 on 15 May 2024.
The largest trade he's ever made was exercising 86,000 units of Vertex Pharmaceuticals stock on 30 September 2014 worth over $3,244,780. On average, Amit trades about 8,244 units every 43 days since 2007. As of 15 May 2024 he still owns at least 55,325 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Sachdev stock trades at the bottom of the page.
Amit K. Sachdev, J.D., is Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO of the Vertex Pharmaceuticals Incorporated. He served as our Executive Vice President, Policy, Access and Value, from October 2014 through December 2016. In 2007, he joined us as a Senior Vice President, and has led our government affairs and public policy activities, as well as our patient advocacy programs. From 2010 through 2013 he established our first international commercial operations in Canada. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health of the Biotechnology Industry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the United States House of Representatives and practiced law at the Chemical Manufacturers Association, and subsequently at the law firm of Ropes & Gray LLP. Mr. Sachdev holds a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.
As the Executive Vice President and Chief Regulatory Officer and Chief of Staff to the CEO of Vertex Pharmaceuticals, the total compensation of Amit Sachdev at Vertex Pharmaceuticals is $6,197,050. There are 3 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Amit Sachdev is 51, he's been the Executive Vice President and Chief Regulatory Officer and Chief of Staff to the CEO of Vertex Pharmaceuticals since 2017. There are 17 older and 6 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Amit's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: